Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma.

Castella B, Riganti C, Massaia M.

Front Biosci (Landmark Ed). 2020 Jan 1;25:69-105.

PMID:
31585878
2.

New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer.

Riganti C, Contino M.

Int J Mol Sci. 2019 Sep 26;20(19). pii: E4783. doi: 10.3390/ijms20194783.

3.

Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.

Teodori E, Contino M, Riganti C, Bartolucci G, Braconi L, Manetti D, Romanelli MN, Trezza A, Athanasios A, Spiga O, Perrone MG, Giampietro R, Gazzano E, Salerno M, Colabufo NA, Dei S.

Eur J Med Chem. 2019 Aug 30;182:111655. doi: 10.1016/j.ejmech.2019.111655. [Epub ahead of print]

PMID:
31494468
4.

What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg.

Alexa-Stratulat T, Pešić M, Gašparović AČ, Trougakos IP, Riganti C.

Drug Resist Updat. 2019 Aug 23;46:100643. doi: 10.1016/j.drup.2019.100643. [Epub ahead of print]

PMID:
31493711
5.

Correction to: The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma.

Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P.

Cell Death Differ. 2019 Sep 5. doi: 10.1038/s41418-019-0405-7. [Epub ahead of print]

PMID:
31488891
6.

European Cardiac Arrhythmia Society Statement on the cardiovascular events associated with the use or abuse of energy drinks.

Lévy S, Santini L, Capucci A, Oto A, Santomauro M, Riganti C, Raviele A, Cappato R.

J Interv Card Electrophysiol. 2019 Oct;56(1):99-115. doi: 10.1007/s10840-019-00610-2. Epub 2019 Sep 3. Review.

PMID:
31482331
7.

Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug.

Sodano F, Lazzarato L, Rolando B, Spyrakis F, De Caro C, Magliocca S, Marabello D, Chegaev K, Gazzano E, Riganti C, Calignano A, Russo R, Rimoli MG.

Mol Pharm. 2019 Oct 7;16(10):4181-4189. doi: 10.1021/acs.molpharmaceut.9b00508. Epub 2019 Sep 12.

PMID:
31465230
8.

Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury.

Bonezzi F, Piccoli M, Dei Cas M, Paroni R, Mingione A, Monasky MM, Caretti A, Riganti C, Ghidoni R, Pappone C, Anastasia L, Signorelli P.

Front Physiol. 2019 Aug 9;10:986. doi: 10.3389/fphys.2019.00986. eCollection 2019.

9.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

10.

The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma.

Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P.

Cell Death Differ. 2019 Jul 8. doi: 10.1038/s41418-019-0386-6. [Epub ahead of print] Erratum in: Cell Death Differ. 2019 Sep 5;:.

PMID:
31285546
11.

Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.

Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C.

Mol Pharm. 2019 Aug 5;16(8):3361-3373. doi: 10.1021/acs.molpharmaceut.9b00018. Epub 2019 Jul 2.

PMID:
31265310
12.

"Three-Bullets" Loaded Mesoporous Silica Nanoparticles for Combined Photo/Chemotherapy.

Tessaro AL, Fraix A, Pedrozo da Silva AC, Gazzano E, Riganti C, Sortino S.

Nanomaterials (Basel). 2019 May 31;9(6). pii: E823. doi: 10.3390/nano9060823.

13.

ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.

Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C.

Int J Mol Sci. 2019 May 21;20(10). pii: E2505. doi: 10.3390/ijms20102505. Review.

14.

Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.

Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, Orecchia S, Ananthanarayanan P, Bironzo P, Grosso F, Tabbò F, Comunanza V, Alexa-Stratulat T, Bussolino F, Righi L, Novello S, Scagliotti GV, Riganti C.

Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32419. [Epub ahead of print]

PMID:
31107974
15.

Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?

Kopecka J, Gazzano E, Castella B, Salaroglio IC, Mungo E, Massaia M, Riganti C.

Semin Cell Dev Biol. 2019 May 18. pii: S1084-9521(18)30164-2. doi: 10.1016/j.semcdb.2019.05.008. [Epub ahead of print] Review.

PMID:
31100351
16.

Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.

Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbò F, Cartia CF, Passone E, Comunanza V, Ardissone F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C.

J Thorac Oncol. 2019 Aug;14(8):1458-1471. doi: 10.1016/j.jtho.2019.03.029. Epub 2019 May 9.

17.

Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae.

Parisi C, Failla M, Fraix A, Rolando B, Gianquinto E, Spyrakis F, Gazzano E, Riganti C, Lazzarato L, Fruttero R, Gasco A, Sortino S.

Chemistry. 2019 Aug 22;25(47):11080-11084. doi: 10.1002/chem.201902062. Epub 2019 Jul 4.

PMID:
31074543
18.

Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.

Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, Saponara S, Sorge M, Hattinger CM, Gasco A, Fruttero R, Brancaccio M, Serra M, Stella B, Fattal E, Arpicco S, Riganti C.

Cancer Lett. 2019 Aug 1;456:29-39. doi: 10.1016/j.canlet.2019.04.029. Epub 2019 Apr 29.

PMID:
31047947
19.

Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.

Mujumdar P, Kopecka J, Bua S, Supuran CT, Riganti C, Poulsen SA.

J Med Chem. 2019 Apr 25;62(8):4174-4192. doi: 10.1021/acs.jmedchem.9b00282. Epub 2019 Apr 10.

PMID:
30925064
20.

Correction to "Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance".

Chegaev K, Fraix A, Gazzano E, Abd-Ellatef GEF, Blangetti M, Rolando B, Conoci S, Riganti C, Fruttero R, Gasco A, Sortino S.

ACS Med Chem Lett. 2019 Feb 28;10(3):393. doi: 10.1021/acsmedchemlett.9b00048. eCollection 2019 Mar 14.

21.

Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution.

Muntoni E, Martina K, Marini E, Giorgis M, Lazzarato L, Salaroglio IC, Riganti C, Lanotte M, Battaglia L.

Pharmaceutics. 2019 Feb 2;11(2). pii: E65. doi: 10.3390/pharmaceutics11020065.

22.

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.

Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, Schally AV, Granata R.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2226-2231. doi: 10.1073/pnas.1818865116. Epub 2019 Jan 18.

23.

Pro- and anti-oxidant properties of near-infrared (NIR) light responsive carbon nanoparticles.

Kokalari I, Gassino R, Giovannozzi AM, Croin L, Gazzano E, Bergamaschi E, Rossi AM, Perrone G, Riganti C, Ponti J, Fenoglio I.

Free Radic Biol Med. 2019 Apr;134:165-176. doi: 10.1016/j.freeradbiomed.2019.01.013. Epub 2019 Jan 11.

PMID:
30639569
24.

Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2-neo mouse rescued by L-type calcium channel blockers.

Calorio C, Gavello D, Guarina L, Salio C, Sassoè-Pognetto M, Riganti C, Bianchi FT, Hofer NT, Tuluc P, Obermair GJ, Defilippi P, Balzac F, Turco E, Bett GC, Rasmusson RL, Carbone E.

J Physiol. 2019 Mar;597(6):1705-1733. doi: 10.1113/JP277487. Epub 2019 Jan 28.

PMID:
30629744
25.

Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells.

Riganti C, Contino M, Guglielmo S, Perrone MG, Salaroglio IC, Milosevic V, Giampietro R, Leonetti F, Rolando B, Lazzarato L, Colabufo NA, Fruttero R.

J Med Chem. 2019 Jan 24;62(2):974-986. doi: 10.1021/acs.jmedchem.8b01655. Epub 2019 Jan 9.

PMID:
30584838
26.

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.

Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J.

J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0.

27.

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.

Castella B, Melaccio A, Foglietta M, Riganti C, Massaia M.

Front Oncol. 2018 Nov 6;8:508. doi: 10.3389/fonc.2018.00508. eCollection 2018. Review.

28.

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.

Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omedè P, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R.

Blood. 2019 Jan 10;133(2):156-167. doi: 10.1182/blood-2018-05-850826. Epub 2018 Nov 19.

PMID:
30455381
29.

Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.

Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, Rolando B, Fruttero R, Gasco A, Hattinger C, Serra M, Riganti C.

Cell Mol Life Sci. 2019 Feb;76(3):609-625. doi: 10.1007/s00018-018-2967-9. Epub 2018 Nov 14.

PMID:
30430199
30.

Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity.

Butera G, Pacchiana R, Mullappilly N, Margiotta M, Bruno S, Conti P, Riganti C, Donadelli M.

Biochim Biophys Acta Mol Cell Res. 2018 Dec;1865(12):1914-1923. doi: 10.1016/j.bbamcr.2018.10.005. Epub 2018 Oct 5.

31.

Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.

Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, Poulsen SA, Riganti C.

Mol Cancer Ther. 2018 Dec;17(12):2598-2609. doi: 10.1158/1535-7163.MCT-18-0533. Epub 2018 Sep 25.

PMID:
30254183
32.

New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands.

Contino M, Guglielmo S, Perrone MG, Giampietro R, Rolando B, Carrieri A, Zaccaria D, Chegaev K, Borio V, Riganti C, Zabielska-Koczywąs K, Colabufo NA, Fruttero R.

Medchemcomm. 2018 Apr 3;9(5):862-869. doi: 10.1039/c8md00075a. eCollection 2018 May 1.

33.

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.

Castella B, Foglietta M, Riganti C, Massaia M.

Front Immunol. 2018 Jun 25;9:1492. doi: 10.3389/fimmu.2018.01492. eCollection 2018. Review.

34.

ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.

Riganti C, Castella B, Massaia M.

Front Immunol. 2018 Jun 8;9:1246. doi: 10.3389/fimmu.2018.01246. eCollection 2018. Review.

35.

Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells.

Gazzano E, Lazzarato L, Rolando B, Kopecka J, Guglielmo S, Costamagna C, Chegaev K, Riganti C.

Front Pharmacol. 2018 Jun 4;9:580. doi: 10.3389/fphar.2018.00580. eCollection 2018.

36.

Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations.

Magliocca S, De Caro C, Lazzarato L, Russo R, Rolando B, Chegaev K, Marini E, Nieddu M, Burrai L, Boatto G, Cristiano C, Marabello D, Gazzano E, Riganti C, Sodano F, Rimoli MG.

Mol Pharm. 2018 Aug 6;15(8):3101-3110. doi: 10.1021/acs.molpharmaceut.8b00195. Epub 2018 Jun 27.

PMID:
29912563
37.

New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro.

Salaroglio IC, Gazzano E, Kopecka J, Chegaev K, Costamagna C, Fruttero R, Guglielmo S, Riganti C.

Molecules. 2018 Jun 9;23(6). pii: E1401. doi: 10.3390/molecules23061401.

38.

An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.

von Neubeck B, Gondi G, Riganti C, Pan C, Parra Damas A, Scherb H, Ertürk A, Zeidler R.

Int J Cancer. 2018 Oct 15;143(8):2065-2075. doi: 10.1002/ijc.31607. Epub 2018 Aug 10.

39.

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.

Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C.

Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26.

PMID:
29748013
40.

Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting.

Wyart E, Reano S, Hsu MY, Longo DL, Li M, Hirsch E, Filigheddu N, Ghigo A, Riganti C, Porporato PE.

Oxid Med Cell Longev. 2018 Feb 26;2018:6419805. doi: 10.1155/2018/6419805. eCollection 2018.

41.

Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor.

Sodano F, Rolando B, Spyrakis F, Failla M, Lazzarato L, Gazzano E, Riganti C, Fruttero R, Gasco A, Sortino S.

ChemMedChem. 2018 Jun 20;13(12):1238-1245. doi: 10.1002/cmdc.201800088. Epub 2018 May 8.

PMID:
29633541
42.

New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.

Bigagli E, Luceri C, De Angioletti M, Chegaev K, D'Ambrosio M, Riganti C, Gazzano E, Saponara S, Longini M, Luceri F, Cinci L.

Invest New Drugs. 2018 Dec;36(6):985-998. doi: 10.1007/s10637-018-0590-0. Epub 2018 Apr 2.

PMID:
29607467
43.

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R.

Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.

44.

Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors.

Pati ML, Niso M, Spitzer D, Berardi F, Contino M, Riganti C, Hawkins WG, Abate C.

Eur J Med Chem. 2018 Jan 20;144:359-371. doi: 10.1016/j.ejmech.2017.12.024. Epub 2017 Dec 8.

45.

ω-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy.

Corsetto PA, Colombo I, Kopecka J, Rizzo AM, Riganti C.

Int J Mol Sci. 2017 Dec 20;18(12). pii: E2770. doi: 10.3390/ijms18122770. Review.

46.

Endogenous glutamine decrease is associated with pancreatic cancer progression.

Roux C, Riganti C, Borgogno SF, Curto R, Curcio C, Catanzaro V, Digilio G, Padovan S, Puccinelli MP, Isabello M, Aime S, Cappello P, Novelli F.

Oncotarget. 2017 Aug 24;8(56):95361-95376. doi: 10.18632/oncotarget.20545. eCollection 2017 Nov 10.

47.

Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.

Gazzano E, Rolando B, Chegaev K, Salaroglio IC, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C.

J Control Release. 2018 Jan 28;270:37-52. doi: 10.1016/j.jconrel.2017.11.042. Epub 2017 Dec 2.

PMID:
29191785
48.

A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery.

Sodano F, Gazzano E, Fraix A, Rolando B, Lazzarato L, Russo M, Blangetti M, Riganti C, Fruttero R, Gasco A, Sortino S.

ChemMedChem. 2018 Jan 8;13(1):87-96. doi: 10.1002/cmdc.201700608. Epub 2017 Nov 30.

PMID:
29110418
49.

Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.

Stama ML, Ślusarczyk J, Lacivita E, Kirpotina LN, Schepetkin IA, Chamera K, Riganti C, Perrone R, Quinn MT, Basta-Kaim A, Leopoldo M.

Eur J Med Chem. 2017 Dec 1;141:703-720. doi: 10.1016/j.ejmech.2017.09.023. Epub 2017 Sep 18.

50.

FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis.

Chattaragada MS, Riganti C, Sassoe M, Principe M, Santamorena MM, Roux C, Curcio C, Evangelista A, Allavena P, Salvia R, Rusev B, Scarpa A, Cappello P, Novelli F.

Oncogene. 2018 Feb 8;37(6):697-709. doi: 10.1038/onc.2017.358. Epub 2017 Oct 23.

Supplemental Content

Loading ...
Support Center